{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:13:36Z","timestamp":1790741616667,"version":"4.1.0"},"reference-count":57,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), leg type (PCDLBCL-LT) is a rare subset of DLBCL that exhibits genetic features shared with LBCL of immune-privileged sites (notably the MYD88L265P mutation) and is enriched in tumor-associated macrophages expressing M2 markers. Using a unique PCDLBCL-LT cell line (ARSI cell line) developed in our institute, we sought to mechanistically decipher the interplay between lymphoma cells and macrophages. We demonstrate that ARSI cells induce phenotypic, transcriptional, and functional changes in macrophages obtained from primary monocytes and THP-1 cell line. These changes do not require cell-cell contact, and proteome analysis of ARSI secretome reveals high concentration of several cytokines and chemokines known to affect macrophages, including interleukin-10 (IL-10). We then demonstrate that IL-10\/Interleukin 10 receptor subunit alpha (IL-10RA) interaction blockade inhibits macrophage polarization induced by tumor cells. These findings are reproduced when macrophages are cocultured with PCDLBCL-LT cells from different patient-derived xenografts. However, among 4 other DLBCL cell lines, only the MYD88-mutated OCI-Ly3 cell line exhibits similar effects, which highlights the variability of macrophage interplays and led us to hypothesize that macrophage shaping, beyond the cutaneous localization, may rely on specific genetics of tumor cells. Finally, we reveal that macrophages enhance tumor cell proliferation and promote resistance to doxorubicin in coculture. In conclusion, these results confirm the robustness of this model to study lymphoma cell and macrophage interplays, underline the critical role of IL-10 in lymphoma microenvironment modeling, and may contribute to better defining its specificities in an era of rising microenvironment-targeted therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016492","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T13:57:17Z","timestamp":1765202237000},"page":"850-863","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Cutaneous diffuse large B-cell lymphoma induces a macrophage immunosuppressive phenotype through IL-10 secretion"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2176-227X","authenticated-orcid":false,"given":"Jean","family":"Galtier","sequence":"first","affiliation":[{"name":"1Bordeaux Institute of Oncology, Unit\u00e9 Mixte de Recherche 1312, INSERM, University of Bordeaux, Team 5, Bordeaux, France"},{"name":"2Hematology and Cell Therapy Department, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0407-7169","authenticated-orcid":false,"given":"Remi","family":"Peanne","sequence":"additional","affiliation":[{"name":"1Bordeaux Institute of Oncology, Unit\u00e9 Mixte de Recherche 1312, INSERM, University of Bordeaux, Team 5, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2408-4344","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Le Morvan","sequence":"additional","affiliation":[{"name":"1Bordeaux Institute of Oncology, Unit\u00e9 Mixte de Recherche 1312, INSERM, University of Bordeaux, Team 5, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Blondy","sequence":"additional","affiliation":[{"name":"1Bordeaux Institute of Oncology, Unit\u00e9 Mixte de Recherche 1312, INSERM, University of Bordeaux, Team 5, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00eflys","family":"Melane","sequence":"additional","affiliation":[{"name":"1Bordeaux Institute of Oncology, Unit\u00e9 Mixte de Recherche 1312, INSERM, University of Bordeaux, Team 5, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9308-584X","authenticated-orcid":false,"given":"Aurore","family":"Bidon","sequence":"additional","affiliation":[{"name":"1Bordeaux Institute of Oncology, Unit\u00e9 Mixte de Recherche 1312, INSERM, University of Bordeaux, Team 5, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0416-9383","authenticated-orcid":false,"given":"Arnaud","family":"Chopin","sequence":"additional","affiliation":[{"name":"1Bordeaux Institute of Oncology, Unit\u00e9 Mixte de Recherche 1312, INSERM, University of Bordeaux, Team 5, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7719-7679","authenticated-orcid":false,"given":"Martina","family":"Prochazkova-Carlotti","sequence":"additional","affiliation":[{"name":"1Bordeaux Institute of Oncology, Unit\u00e9 Mixte de Recherche 1312, INSERM, University of Bordeaux, Team 5, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8783-0709","authenticated-orcid":false,"given":"Sandrine","family":"Poglio","sequence":"additional","affiliation":[{"name":"1Bordeaux Institute of Oncology, Unit\u00e9 Mixte de Recherche 1312, INSERM, University of Bordeaux, Team 5, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0305-0850","authenticated-orcid":false,"given":"Jean-Philippe","family":"Merlio","sequence":"additional","affiliation":[{"name":"1Bordeaux Institute of Oncology, Unit\u00e9 Mixte de Recherche 1312, INSERM, University of Bordeaux, Team 5, Bordeaux, France"},{"name":"3Tumor Bank and Tumor Biology Laboratory, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9724-8437","authenticated-orcid":false,"given":"Edith","family":"Chevret","sequence":"additional","affiliation":[{"name":"1Bordeaux Institute of Oncology, Unit\u00e9 Mixte de Recherche 1312, INSERM, University of Bordeaux, Team 5, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8958-3745","authenticated-orcid":false,"given":"Audrey","family":"Gros","sequence":"additional","affiliation":[{"name":"1Bordeaux Institute of Oncology, Unit\u00e9 Mixte de Recherche 1312, INSERM, University of Bordeaux, Team 5, Bordeaux, France"},{"name":"3Tumor Bank and Tumor Biology Laboratory, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2960-6084","authenticated-orcid":false,"given":"Anne","family":"Pham-Ledard","sequence":"additional","affiliation":[{"name":"1Bordeaux Institute of Oncology, Unit\u00e9 Mixte de Recherche 1312, INSERM, University of Bordeaux, Team 5, Bordeaux, France"},{"name":"4Dermatology Department, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-1229","authenticated-orcid":false,"given":"Marie","family":"Beylot-Barry","sequence":"additional","affiliation":[{"name":"1Bordeaux Institute of Oncology, Unit\u00e9 Mixte de Recherche 1312, INSERM, University of Bordeaux, Team 5, Bordeaux, France"},{"name":"4Dermatology Department, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8829-9945","authenticated-orcid":false,"given":"Laurence","family":"Bresson-Bepoldin","sequence":"additional","affiliation":[{"name":"1Bordeaux Institute of Oncology, Unit\u00e9 Mixte de Recherche 1312, INSERM, University of Bordeaux, Team 5, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"1","key":"2026021015522842600_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41408-020-00403-1","article-title":"Incidence of relapsed\/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden","volume":"11","author":"Harrysson","year":"2021","journal-title":"Blood Cancer J"},{"issue":"15","key":"2026021015522842600_bib2","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026021015522842600_bib3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","article-title":"Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial","volume":"20","author":"Davies","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"2026021015522842600_bib4","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.20.01366","article-title":"ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6769","key":"2026021015522842600_bib5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"15","key":"2026021015522842600_bib6","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"2026021015522842600_bib7","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"issue":"20","key":"2026021015522842600_bib8","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2026021015522842600_bib9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"9","key":"2026021015522842600_bib10","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1038\/bcj.2013.28","article-title":"High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites","volume":"3","author":"Kraan","year":"2013","journal-title":"Blood Cancer J"},{"issue":"6","key":"2026021015522842600_bib11","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","article-title":"Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures","volume":"11","author":"Kotlov","year":"2021","journal-title":"Cancer Discov"},{"issue":"16","key":"2026021015522842600_bib12","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1182\/bloodadvances.2023009813","article-title":"Diffuse large B-cell lymphomas have spatially-defined tumor-immune microenvironments revealed by high-parameter imaging","volume":"7","author":"Wright","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"2026021015522842600_bib13","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood.2023021002","article-title":"Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B-cell lymphoma","volume":"143","author":"Cerchietti","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2026021015522842600_bib14","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"2026021015522842600_bib15","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.jid.2017.04.010","article-title":"Identification of somatic mutations in primary cutaneous diffuse large B-cell lymphoma, leg type by massive parallel sequencing","volume":"137","author":"Mareschal","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"8","key":"2026021015522842600_bib16","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1038\/jid.2012.102","article-title":"MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"132","author":"Pham-Ledard","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"11","key":"2026021015522842600_bib17","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2014.821","article-title":"High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type","volume":"150","author":"Pham-Ledard","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"3","key":"2026021015522842600_bib18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/PAS.0000000000000983","article-title":"PD-L1 and PD-L2 are differentially expressed by macrophages or tumor cells in primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"42","author":"Menguy","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"2026021015522842600_bib19","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jid.2022.08.043","article-title":"Patient-derived xenograft and cell line models of human primary cutaneous diffuse large B-cell lymphoma-leg type","volume":"143","author":"Prochazkova-Carlotti","year":"2023","journal-title":"J Invest Dermatol"},{"issue":"8","key":"2026021015522842600_bib20","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.immuni.2021.07.007","article-title":"Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease","volume":"54","author":"Mulder","year":"2021","journal-title":"Immunity"},{"issue":"1","key":"2026021015522842600_bib21","doi-asserted-by":"crossref","first-page":"14333","DOI":"10.1038\/s41598-020-70353-y","article-title":"Single-cell RNA sequencing uncovers heterogenous transcriptional signatures in macrophages during efferocytosis","volume":"10","author":"Lantz","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"2026021015522842600_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","article-title":"Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance","volume":"8","author":"Wang","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"2026021015522842600_bib23","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1186\/s12885-019-6208-x","article-title":"Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count","volume":"19","author":"Li","year":"2019","journal-title":"BMC Cancer"},{"issue":"2","key":"2026021015522842600_bib24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/hon.2142","article-title":"High density of CD68+\/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma","volume":"33","author":"Marchesi","year":"2015","journal-title":"Hematol Oncol"},{"issue":"8","key":"2026021015522842600_bib25","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med"},{"issue":"4","key":"2026021015522842600_bib26","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1158\/1078-0432.CCR-21-3140","article-title":"Clinical impact of immune cells and their spatial interactions in diffuse large B-cell lymphoma microenvironment","volume":"28","author":"Autio","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2026021015522842600_bib27","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ccell.2015.02.015","article-title":"Macrophages and therapeutic resistance in cancer","volume":"27","author":"Ruffell","year":"2015","journal-title":"Cancer Cell"},{"issue":"5","key":"2026021015522842600_bib28","doi-asserted-by":"crossref","first-page":"109955","DOI":"10.1016\/j.celrep.2021.109955","article-title":"Global characterization of macrophage polarization mechanisms and identification of M2-type polarization inhibitors","volume":"37","author":"He","year":"2021","journal-title":"Cell Rep"},{"issue":"11","key":"2026021015522842600_bib29","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nri3088","article-title":"Transcriptional regulation of macrophage polarization: enabling diversity with identity","volume":"11","author":"Lawrence","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"18","key":"2026021015522842600_bib30","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res"},{"issue":"2","key":"2026021015522842600_bib31","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.immuni.2014.01.006","article-title":"Transcriptome-based network analysis reveals a spectrum model of human macrophage activation","volume":"40","author":"Xue","year":"2014","journal-title":"Immunity"},{"issue":"1","key":"2026021015522842600_bib32","doi-asserted-by":"crossref","first-page":"7389","DOI":"10.1038\/s41467-022-35095-7","article-title":"Integrated proteomic and transcriptomic landscape of macrophages in mouse tissues","volume":"13","author":"Qie","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"2026021015522842600_bib33","doi-asserted-by":"crossref","first-page":"10740","DOI":"10.1038\/s41467-024-54512-7","article-title":"Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma","volume":"15","author":"Paczkowska","year":"2024","journal-title":"Nat Commun"},{"issue":"11","key":"2026021015522842600_bib34","doi-asserted-by":"crossref","first-page":"e155022","DOI":"10.1172\/jci.insight.155022","article-title":"CD206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity","volume":"7","author":"Modak","year":"2022","journal-title":"JCI Insight"},{"issue":"21","key":"2026021015522842600_bib35","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1182\/bloodadvances.2021004203","article-title":"The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5","volume":"5","author":"Manfroi","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"2026021015522842600_bib36","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41375-019-0573-y","article-title":"A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL","volume":"34","author":"Staiger","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"2026021015522842600_bib37","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/PAS.0000000000000851","article-title":"Tumor microenvironment and checkpoint molecules in primary cutaneous diffuse large B-cell lymphoma-new therapeutic targets","volume":"41","author":"Mitteldorf","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"2026021015522842600_bib38","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.trecan.2022.02.006","article-title":"C1q+ macrophages: passengers or drivers of cancer progression","volume":"8","author":"Revel","year":"2022","journal-title":"Trends Cancer"},{"issue":"Pt 1","key":"2026021015522842600_bib39","doi-asserted-by":"crossref","first-page":"113319","DOI":"10.1016\/j.intimp.2024.113319","article-title":"Single-cell sequencing in diffuse large B-cell lymphoma: C1qC is a potential tumor-promoting factor","volume":"143","author":"Gao","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"18","key":"2026021015522842600_bib40","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.2024025652","article-title":"DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma","volume":"145","author":"Chapuy","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026021015522842600_bib41","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1182\/blood-2023-173394","article-title":"Remodeling of the immune microenvironment by oncogenic MYD88 dictates immunotherapy responses across indolent and aggressive B-cell lymphomas","volume":"142","author":"Celay","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026021015522842600_bib42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"issue":"5","key":"2026021015522842600_bib43","first-page":"2253","article-title":"Shaping gene expression in activated and resting primary macrophages by IL-10","volume":"169","author":"Lang","year":"2002","journal-title":"J Immunol 1950"},{"issue":"23","key":"2026021015522842600_bib44","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1182\/blood.2024025755","article-title":"IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy","volume":"145","author":"Garcia-Lacarte","year":"2025","journal-title":"Blood"},{"issue":"8","key":"2026021015522842600_bib45","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/leu.2015.57","article-title":"IL10 receptor is a novel therapeutic target in DLBCLs","volume":"29","author":"B\u00e9guelin","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"2026021015522842600_bib46","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","article-title":"Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma","volume":"111","author":"Lam","year":"2008","journal-title":"Blood"},{"issue":"7332","key":"2026021015522842600_bib47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"issue":"7718","key":"2026021015522842600_bib48","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","article-title":"A multiprotein supercomplex controlling oncogenic signalling in lymphoma","volume":"560","author":"Phelan","year":"2018","journal-title":"Nature"},{"issue":"17","key":"2026021015522842600_bib49","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood-2018-03-841015","article-title":"B-cell receptor\u2013mediated NFATc1 activation induces IL-10\/STAT3\/PD-L1 signaling in diffuse large B-cell lymphoma","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2026021015522842600_bib50","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.4049\/jimmunol.172.3.1407","article-title":"CCL17 and IL-10 as effectors that enable alternatively activated macrophages to inhibit the generation of classically activated macrophages","volume":"172","author":"Katakura","year":"2004","journal-title":"J Immunol"},{"issue":"12","key":"2026021015522842600_bib51","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.it.2004.09.015","article-title":"The chemokine system in diverse forms of macrophage activation and polarization","volume":"25","author":"Mantovani","year":"2004","journal-title":"Trends Immunol"},{"issue":"1","key":"2026021015522842600_bib52","doi-asserted-by":"crossref","first-page":"31580","DOI":"10.1038\/s41598-024-75750-1","article-title":"The expression of CCL17 and potential prognostic value on tumor immunity in thyroid carcinoma based on bioinformatics analysis","volume":"14","author":"Gu","year":"2024","journal-title":"Sci Rep"},{"issue":"12","key":"2026021015522842600_bib53","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1182\/blood-2011-10-388538","article-title":"Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation","volume":"119","author":"Gupta","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2026021015522842600_bib54","doi-asserted-by":"crossref","first-page":"2003533","DOI":"10.1080\/2162402X.2021.2003533","article-title":"Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma","volume":"10","author":"Stirm","year":"2021","journal-title":"Oncoimmunology"},{"issue":"22","key":"2026021015522842600_bib55","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1182\/bloodadvances.2024013277","article-title":"Magrolimab plus rituximab in relapsed\/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1\/2 trial","volume":"8","author":"Mehta","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"2026021015522842600_bib56","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/s41375-024-02391-8","article-title":"IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma","volume":"38","author":"Sun","year":"2024","journal-title":"Leukemia"},{"issue":"6","key":"2026021015522842600_bib57","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/3\/850\/2502253\/blooda_adv-2025-016492-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/3\/850\/2502253\/blooda_adv-2025-016492-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:52:40Z","timestamp":1770756760000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/3\/850\/557100\/Cutaneous-diffuse-large-B-cell-lymphoma-induces-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016492","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,10]]},"published":{"date-parts":[[2026,2,2]]}}}